Results 1 to 10 of about 4,550 (156)
Some of the next articles are maybe not open access.
Immunotoxins and Recombinant Immunotoxins in Cancer Therapy
2006 Targeted cancer therapy in general and immunotherapy in particular, combines rational drug design with the progress in understanding cancer biology. This approach takes advantage of our recent knowledge of the mechanisms by which normal cells are transformed into cancer cells, thus, using the special properties of cancer cells to device novel ...Yoram Reiter, Avital Levopenaire +1 more sourceImmunotoxins
2010 Marilyn E. Carroll, Peter A. Santi, Joseph Zohar, Thomas R. E. Barnes, Peter Verheart, Per Svenningsson, Per E. Andrén, Lawrence H. Price, Johannes Wancata, Kim Fromme, Amee B. Patel, Anthony R. Isles, Lawrence S. Wilkinson, Jon E. Grant, Brian L. Odlaug, Rosa M. M. de Almeida, Klaus A. Miczek, Suzanne H. Mitchell, de Harriet Wit, Alyson J. Bond, Anthony L. Riley, Steve Kohut, Alex Hofer, Darren R. Christensen, Warren K. Bickel, Suzanne H. Mitchell, Harriet de Wit, Stephen C. Fowler, Pedro L. Delgado, Etienne Sibille, Nicole Edgar, Maria-Inés López-Ibor, Juan J. López-Ibor, Robert L. Balster, Celia J. A. Morgan, Valerie H. Curran, Hans Möhler, Malcolm Lader, Anthony Dickinson, Peter Riederer, Siegfried Hoyer, Josee E. Leysen, Jos Prickaerts, Michael M. Morgan, MacDonald J. Christie, Lawrence H. Price, Warren H. Meck, Catalin V. Buhushi, Rodrigo Andrade, Peter Shizgal, Giovanni Hernandez, David S. Tait, Verity J. Brown, Gail Winger, Mei-Chuan Ko, James H. Woods, Peter J. Tyrer, Gregory D. Stewart, Patrick M. Sexton, Arthur Christopoulos, Mischa De Rover, Sander Nieuwenhuis, Trevor W. Robbins, Mark Slifstein, Lawrence H. Price, Michael J. Owens, Chase H. Bourke, Bart Ellenbroek, Bankole A. Johnson +68 moreopenaire +1 more source
